Skip to main content Back to Top
Advertisement

7/19/2022

Rifampin Injection

Products Affected - Description

    • Rifampin lyophilized powder for injection, Fresenius Kabi, 600 mg, vial, 1 count, NDC 63323-0351-20
    • Rifampin lyophilized powder for injection, Mylan Institutional, 600 mg, vial, 1 count, NDC 67457-0445-60

Reason for the Shortage

    • Fresenius Kabi did not provide a reason for the shortage.
    • Mylan Institutional did not provide a reason for the shortage.
    • Sanofi has Rifadin IV available.

Available Products

    • Rifadin IV lyophilized powder for injection, Sanofi-Aventis, 600 mg, vial, 1 count, NDC 00068-0597-01

Estimated Resupply Dates

    • Fresenius Kabi has rifampin 600 mg vials on back order and the company estimates a release date of late-August 2022.
    • Mylan Institutional has rifampin 600 mg vials on back order and the company estimates a release date of late-July 2022.

Updated

Updated July 19, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created December 28, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.